# Impact of Different BRCA1/2 Gene Variants on Response to Therapy and Prognosis of Ovarian Cancer

> **NCT06775470** · — · RECRUITING · sponsor: **IRCCS Azienda Ospedaliero-Universitaria di Bologna** · enrollment: 300 (estimated)

## Conditions studied

- Ovarian Cancer

## Interventions

- **DIAGNOSTIC_TEST:** Patients must have been diagnosed with ovarian cancer and be BRCA positive
- **DIAGNOSTIC_TEST:** BRCA1 and BRCA2 positive, and be affected by Ovarian Cancer

## Key facts

- **NCT ID:** NCT06775470
- **Lead sponsor:** IRCCS Azienda Ospedaliero-Universitaria di Bologna
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2022-07-01
- **Primary completion:** 2025-12-31
- **Final completion:** 2025-12-31
- **Target enrollment:** 300 (ESTIMATED)
- **Last updated:** 2025-01-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06775470

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06775470, "Impact of Different BRCA1/2 Gene Variants on Response to Therapy and Prognosis of Ovarian Cancer". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT06775470. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*